Value of Collaboration in Managing Patients With Metastatic RCC
Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Novel Therapy in Metastatic RCC: An Evolving Treatment Landscape
Expert panelists share their perspective on novel and combination strategies being investigated in the setting of metastatic renal cell carcinoma.
Clinical Scenario 2: Favorable-Risk Metastatic Renal Cell Carcinoma
Switching focus to a second clinical scenario, key opinion leaders on metastatic renal cell carcinoma discuss the treatment landscape for favorable-risk disease.
Current Prognoses With Metastatic Renal Cell Carcinoma
Before closing out their review of the first clinical scenario, panelists consider the general state of prognoses within metastatic renal cell carcinoma.
Dose Adjusting Therapy for Patients With Metastatic Renal Cell Carcinoma
A brief review of dose hold or adjustment strategies in the setting of metastatic renal cell carcinoma and when it is appropriate to consider these options.
Metastatic Renal Cell Carcinoma: Communicating Treatment Options With Patients
Shared insight on the treatment armamentarium for metastatic renal cell carcinoma and how these options should be communicated with patients.
Clinical Scenario 1: Renal Cell Carcinoma Diagnosis and Staging
Centering discussion on a clinical scenario of metastatic renal cell carcinoma, expert panelists reflect on optimal diagnosis and stratification methods in this setting.
Clinical Pearls on Recent Advances and the Future of Treatment in RCC
Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Reflections on Novel Targets and Emerging Regimens for RCC
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.
OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
The Importance of Team-Based Management and Patient Communication
Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.
Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
Considerations for Patient-Focused, Shared Decision-Making in RCC
Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.
Patient-Specific Factors Impacting Treatment Choices in RCC
Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.
Strategies for Prevention and Management of Adverse Events
Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.
Balancing Treatment Efficacy with Toxicity in Metastatic RCC
David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.
Common Adverse Events with Single-Agent or Combination Therapy
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.
Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
The Role of Genetic Mutations in Prognosis and Decision-Making
Chung-Han Lee, MD, PhD discusses how genetic mutations inform patient prognosis and decision-making for patients with kidney cancer.
Lee Discusses Future Research for Metastatic RCC
Chung-Han Lee, MD, PhD, spoke about necessary research needed moving forward for patients with metastatic renal cell carcinoma.
Lee Discusses Results From KEYNOTE-146 Trial of Lenvatinib Plus Pembrolizumab
Chung-Han Lee, MD, PhD, spoke about interesting findings that arose from the KEYNOTE-146 study for patients with metastatic renal cell carcinoma.
Chung-Han Lee, MD, PhD, Discusses Biomarkers for Response in RCC With Pembrolizumab Plus Lenvatinib
Chung-Han Lee, MD, PhD, spoke about using biomarkers to help predict responses in patients with metastatic renal cell carcinoma treated on the KEYNOTE-146 study.
Chung-Han Lee, MD, PhD, on TKI/IO Combination Therapy for Non–Clear Cell RCC
At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.
2 Clarke Drive Cranbury, NJ 08512